Is prostate-specific antigen (PSA) density better than the preoperative PSA level in predicting early biochemical recurrence of prostate cancer after radical prostatectomy?

BJU International

Volumn 97, Issue 3, 2006, Pages 480-484

  Jones, Timothy D ^a   Koch, Michael O ^a   Bunde, Paula J ^a   Cheng, Liang ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biochemical recurrence; Neoplasm; Prognosis; Prostate; PSA; PSA density; Radical prostatectomy; Staging

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CHEMICAL ANALYSIS; CORRELATION COEFFICIENT; DENSITY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ORGAN WEIGHT; PATHOLOGY; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL SIGNIFICANCE; TUMOR VOLUME; UNIVARIATE ANALYSIS;

ADULT; AGED; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; ROC CURVE;

EID: 33644996884     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06022.x     Document Type: Article

References (40)

1. Bostwick DG Grignon DJ Hammond ME et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999 Arch Pathol Lab Med 2000 124 995 1000
2. Stamey TA McNeal JE Yemoto CM Sigal BM Johnstone IM Biological determinants of cancer progression in men with prostate cancer JAMA 1999 281 1395 400
3. Stamey TA Johnstone IM McNeal JE Lu AY Yemoto CM Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml J Urol 2002 167 103 11
4. Gonzalez CM Roehl KA Antenor JV Blunt LW Han M Catalona WJ Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy Urology 2004 64 723 8
5. Roehl KA Han M Ramos CG Antenor JA Catalona WJ Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results J Urol 2004 172 910 4
6. Han M Partin AW Zahurak M Piantadosi S Epstein JI Walsh PC Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer J Urol 2003 169 517 23
7. Quinn DI Henshall SM Brenner PC et al. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion Cancer 2003 97 1884 93
8. Han M Partin AW Pound CR Epstein JI Walsh PC Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience Urol Clin North Am 2001 28 555 65
9. Blute ML Bergstralh EJ Iocca A Scherer B Zincke H Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy J Urol 2001 165 119 25
10. Hull GW Rabbani F Abbas F Wheeler TM Kattan MW Scardino PT Cancer control with radical prostatectomy alone in 1,000 consecutive patients J Urol 2002 167 528 34
11. Noguchi M Stamey TA McNeal JE Yemoto CM Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers J Urol 2000 164 1596 600
12. San Francisco IF Regan MM Olumi AF DeWolf WC Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen J Urol 2004 171 1492 9
13. Tombal B Querton M de Nayer P et al. Free/total PSA ratio does not improve prediction of pathologic stage and biochemical recurrence after radical prostatectomy Urology 2002 59 256 60
14. Catalona WJ Southwick PC Slawin KM et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging Urology 2000 56 255 60
15. Kurita Y Suzuki A Masuda H Ushiyama T Suzuki K Fujita K Transition zone volume-adjusted prostate-specific antigen value predicts extracapsular carcinoma of the prostate in patients with intermediate prostate-specific antigen levels Eur Urol 1998 33 32 8
16. Horninger W Rogatsch H Reissigl A et al. Correlation between preoperative predictors and pathologic features in radical prostatectomy specimens in PSA-based screening Prostate 1999 40 56 61
17. Shinohara K Wolf JS Narayan P Carroll PR Comparison of prostate specific antigen with prostate specific antigen density for 3 clinical applications J Urol 1994 152 120 3
18. Ravery V Chastang C Toublanc M Boccon-Gibod L Delmas V Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer Eur Urol 2000 37 449 55
19. Koch MO Foster RS Bell B et al. Characterization and predictors of prostate specific antigen progression rates after radical retropubic prostatectomy J Urol 2000 164 749 53
20. Poulos CK Koch MO Eble JN Daggy JK Cheng L Bladder neck invasion is an independent predictor of prostate-specific antigen recurrence Cancer 2004 101 1563 8
21. Cheng L Koch MO Juliar BE et al. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy J Clin Oncol 2005 23 2911 7
22. Babaian RJ Troncoso P Bhadkamkar VA Johnston DA Analysis of clinicopathologic factors predicting outcome after radical prostatectomy Cancer 2001 91 1414 22
23. van den Ouden D Bentvelsen FM Boeve ER Schroder FH Positive margins after radical prostatectomy: correlation with local recurrence and distant progression Br J Urol 1993 72 489 94
24. Bostwick DG Myers RP Oesterling JE Staging of prostate cancer Semin Surg Oncol 1994 10 60 72
25. Cheng L Darson MF Bergstralh EJ Slezak J Myers RP Bostwick DG Correlation of margin status and extraprostatic extension with progression of prostate carcinoma Cancer 1999 86 1775 82
26. Hong H Koch MO Foster RS et al. Anatomic distribution of periprostatic adipose tissue: a mapping study of 100 radical prostatectomy specimens Cancer 2003 97 1639 43
27. Eichelberger LE Koch MO Daggy JK Ulbright TM Eble JN Cheng L Predicting tumor volume in radical prostatectomy specimens from patients with prostate cancer Am J Clin Pathol 2003 120 386 91
28. Humphrey PA Vollmer RT Intraglandular tumor extent and prognosis in prostatic carcinoma: application of a grid method to prostatectomy specimens Hum Pathol 1990 21 799 804
29. Cheng L Slezak J Bergstralh EJ Myers RP Zincke H Bostwick DG Preoperative prediction of surgical margin status in patients with prostate cancer treated by radical prostatectomy J Clin Oncol 2000 18 2862 8
30. Cheng L Bergstralh EJ Cheville JC et al. Cancer volume of lymph node metastasis predicts progression in prostate cancer Am J Surg Pathol 1998 22 1491 500
31. Gleason DF Mellinger GT Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging J Urol 1974 111 58 64
32. Fleming ID Cooper JS Henson DE et al. AJCC Cancer Staging Manual Philadelphia Raven and Lippincott 1997
33. Eichelberger LE Cheng L Does pT2b prostate carcinoma exist? Critical appraisal of the 2002 TNM classification of prostate carcinoma Cancer 2004 100 2573 6
34. DeLong ER DeLong DM Clarke-Pearson DL Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 1988 44 837 45
35. Blackwell KL Bostwick DG Myers RP Zincke H Oesterling JE Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density J Urol 1994 151 1565 70
36. Khan MA Carter HB Epstein JI et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol 2003 170 2274 8
37. D'Amico AV Chen MH Roehl KA Catalona WJ Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy N Engl J Med 2004 351 125 35
38. Freedland SJ Kane CJ Presti JC et al. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base J Urol 2003 169 969 73
39. Hernandez J Thompson IM Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker Cancer 2004 101 894 904
40. Kattan MW Eastham JA Stapleton AM Wheeler TM Scardino PT A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer J Natl Cancer Inst 1998 90 766 71